International Clinical Trial: A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CLD-423 in Healthy Participants

Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ACTRN12625001454460) titled 'A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CLD-423 in Healthy Participants' on Dec. 19, 2025.

Study Type: Interventional

Study Design: Purpose: Treatment Allocation: Randomised controlled trial

Primary Sponsor: Novotech (Australia) Pty Ltd

Condition: Inflammatory bowel disease Inflammatory bowel disease Inflammatory and Immune System - Other inflammatory or immune system disorders

Intervention: This is a first-in-human (FIH) randomized, double-blind, placebo-controlled study of the safety, tolerability, pharmacokinetics (PK), and pharmacodyn...